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increased understanding of the involvement of ASM’s brisk 
activation in the stress response, little is known about the 
role of baseline ASM activity in maintaining lysosomal func-
tion during physiological conditions. The causal link 
between loss of ASM function and the lipid storage disor-
der, Niemann-Pick disease, revealed a requirement of ASM 
for proper cellular function and highlighted the essential 
role of ASM in sphingomyelin breakdown and lysosomal 
membrane homeostasis (3). Docked at the lysosomal mem-
brane, the lysosomal nutrient-sensing complex (LYNUS) 
controls protein synthesis and autophagy, an essential 
mechanism of cellular survival during stress and starvation 
(4). In turn, aberrant autophagy has been implicated 
in the pathogenesis of several lung diseases, including 
chronic obstructive pulmonary diseases (5). Therefore, 
understanding the molecular determinants of autophagy 
is of clinical importance.
The lysosomal and secreted forms of ASM, both being 
encoded by the sphingomyelin phosphodiesterase 1 (SMPD1) 
gene, catalyze, optimally at acidic pH, the hydrolysis of 
sphingomyelin into ceramide and phosphorylcholine. ASM 
activity is rapidly increased during stress, generating excess 
ceramide that, in turn, interacts with specific signaling mol-
ecules to trigger second messenger effects. In addition, 
ceramide incorporates and alters the biophysical properties 
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The activation above homeostatic levels of acid sphingo-
myelinase (ASM), a lysosomal phosphodiesterase typically 
involved in apoptosis via production of ceramide, has 
recently been implicated in stress-induced macro-autophagy 
(referred to as autophagy, henceforth) (1, 2). Despite 
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of membrane bilayers, such as fluidity and stiffness, by dis-
lodging cholesterol from membrane lipid rafts, impacting 
acyl chain order parameters of neighboring lipids, and 
modifying membrane bilayer composition (6). Because ce-
ramides produced in the lysosome by ASM are not shuttled 
to other subcellular compartments, they may directly influ-
ence the coalescence of microdomains required for lyso-
somal signaling (7). However, ASM forms a molecular 
complex with acid ceramidase, which metabolizes ceramide 
to sphingosine (Sph), a molecule that is, itself, implicated 
in autophagy via alterations of lysosomal calcium efflux 
(8). We investigated to determine whether ASM is required 
for LYNUS function of inhibition of autophagy during 
homeostatic conditions, hypothesizing that inhibition of 
ASM is sufficient to trigger autophagy associated with dis-
rupted LYNUS signaling.
During plentitude of ATP, amino acids, and growth sig-
nals, the mammalian target of rapamycin (mTOR), a ser-
ine/threonine kinase component of LYNUS, stimulates 
protein synthesis (4). This fundamental function of LYNUS 
requires docking to the lysosomal membrane, ensured 
by its farnesylated component, the Ras homolog enriched 
in brain (RHEB) (4). Upon loss of growth signals, mTOR 
becomes inactive and one of its phosphorylation targets in 
LYNUS, transcription factor EB (TFEB), translocates to 
the nucleus, where it upregulates transcription of genes 
involved in lysosomal biogenesis and autophagy, including 
its own (9). When activated above homeostatic levels, such 
as during stress, ASM triggers autophagy with impaired 
lysosomal degradation (decreased autophagic flux) cou-
pled with decreased mRNA transcripts for TFEB targets 
(2). Whether this effect is due to production of excess 
ceramide or to other sphingolipid perturbations remains 
unclear. Such alterations in sphingolipids may either have 
second messenger signaling effects, e.g., excess ceramide 
engages signaling similar to that induced by amino acid 
depletion (10), or could alter the lysosomal membrane 
lipid composition and fluidity, potentially affecting LYNUS 
anchoring.
Utilizing human primary lung endothelial cells, human 
lung epithelial cells, and murine lungs, we show that inhi-
bition of homeostatic ASM activity is sufficient to inactivate 
signaling of LYNUS components and to initiate autophagy 
with degradative potential associated with marked reduc-
tions in Sph, rather than ceramide, levels.
MATERIALS AND METHODS
Reagents
Unless otherwise stated, all reagents were purchased from 
Sigma-Aldrich.
Cell culture
All experiments were performed in full (containing all growth 
supplements) medium unless otherwise stated. Primary human 
pulmonary artery endothelial cells (HPAECs) (Invitrogen, C0085C) 
were cultured in Medium 200 (Invitrogen, M200500) with low 
serum growth supplement (Invitrogen, S00310). Primary human 
lung microvascular endothelial cells (HLMVECs) (Invitrogen, 
CC2527) were cultured in an EGM-2MV BulletKit (Invitrogen, 
CC3202). Primary human umbilical vein endothelial cells 
(HUVECs), a kind gift from Dr. Mathias Clauss (Indiana Univer-
sity), were cultured in VascuLife VEGF medium complete kit 
(LifeLine, LL0003). THP-1 monocytes (ATCC, TIB202) were cul-
tured in RPMI (Invitrogen, 11875119) supplemented with 10% 
FBS (Thermo Fisher Scientific, sh30910-03HI). Immortalized 
bronchial epithelial cells (BEAS2b cells) were cultured in DMEM 
with high glucose and pyruvate (Invitrogen, 11995-073), supple-
mented with 10% FBS and 1% penicillin/streptomycin (Sigma, 
P4333-100ML). All cells were incubated at 37°C with 5% CO2 and 
100% humidity.
ASM inhibition with imipramine
When cells were 80–90% confluent, the medium was replaced 
and imipramine or vehicle was added for the indicated time, when 
cells were washed with 5 ml PBS at 4°C and scraped in 1.5 ml 
PBS at 4°C. Cells were then spun at 16,000 g for 10 min and the 
cell pellets were snap-frozen in liquid nitrogen until assayed.
ASM activity
Lysosomal ASM activity was measured with an Amplex Red 
sphingomyelinase activity kit (Invitrogen, A12220) or radioactiv-
ity. Briefly, the kit utilizes an indirect two-step reaction that pro-
duces a fluorescent readout of ASM activity. Cells were washed in 
ice-cold PBS at the end of treatment, scraped in ice-cold PBS, and 
centrifuged at 16,000 g for 10 min. Supernatant was removed, and 
the remaining cell pellet was snap-frozen in liquid nitrogen. At 
the time of assay, pellets were hydrated with a reaction buffer 
for lysosomal ASM activity, incubated with 5 mM sphingomyelin, 
2 U/ml HRP, and 8 U/ml alkaline phosphatase. Kinetic fluores-
cence measurements were read using a wavelength of 590 nm 
over a period of 2 h at 37°C in a SpectraMax m2e microplate 
reader using SoftMax Pro software.
For the radioactive assay, cells pellets were lysed in 75 l of a 
buffer containing 25 mM Tris (pH 7.6), 5 mM EDTA, 0.2% Triton-X, 
phosphatase inhibitors, and protease inhibitors. To 4 ml of the 
same buffer used to lyse cells, 3.08 l of 14C-choline methyl sphin-
gomyelin at 55 mCi/mmol and 0.1 mCi/ml were added to create 
a substrate buffer (1.4 pmol/l). To 103 l of the reaction buffer, 
35 l of lysate, 12 l of 0.2 M acetic acid, and 50 l of substrate buf-
fer were added, mixed by vortex, and allowed to react at 37°C for 
2.3 h. To stop the reaction, 250 l of a 2:1 (chloroform:methanol) 
solution were added and vortexed. To this, 800 l of a 2:1 
(methanol:chloroform) solution plus 250 l of water were added 
and vortexed. From the aqueous phase, 200 l were extracted 
and added to 800 l of MicroScint PS (Perkin-Elmer, 6013631) 
and radioactivity quantified on a Topcount scintillation counter.
Western blotting
Cells were washed once with ice-cold PBS, gently scraped into 
ice-cold PBS, and centrifuged at 16,000 g for 10 min. Then, the 
supernatant was removed and the pellets were snap-frozen in liq-
uid nitrogen. Cell pellets were thawed at 4°C in cell lysis buffer 
containing 1% Triton-X (EMD, 9002931), 150 mM NaCl (Thermo 
Fisher, BP3581), and 50 mM Tris (pH 7.6; Invitrogen, 15504020) 
and then were vigorously vortexed five times during a 1 h period, 
followed by centrifugation at 4°C for 10 min and the use of the 
supernatant for assays as whole cell lysate.
Protein concentration was determined using BCA (Pierce, 
23227). Equal amounts of protein (2–20 g) were diluted in 
Laemmli 4× buffer (reducing) (Boston Bio Products, NC9099736) 
and resolved in Criterion 12+2-well 4–20% TGX gels (Bio-Rad, 
5671093). A semi-dry transfer apparatus (Bio-Rad, 1703848) was 
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employed to transfer proteins to a polyvinylidene fluoride mem-
brane (EMD, IPVH00010). Membranes were probed with the fol-
lowing antibodies: anti--actin (A5441), anti-microtubule-associated 
protein 1 light chain 3 (LC3B) (Sigma, L7543), anti-vinculin 
(Abcam, ab10858), anti-GAPDH (Abcam, ab9485), anti-phospho 
P70-S6 kinase (P70-S6k) (Thr 389) (Cell Signaling Technologies, 
9205), and anti-phospho mTOR (Ser 2448) (p-mTOR) (Cell 
Signaling Technologies, 5536). Appropriate secondary anti-
bodies (goat anti-rabbit/mouse, HRP conjugate) (GE Healthcare, 
45001175/45001187) were used in conjunction with ECL Prime 
(Thermo Fisher, RPN2232) or Luminata Forte (EMDMillipore, 
WBLUF0500) for chemiluminescent reaction. Images were taken 
with a ChemiDoc (Bio-Rad) XRS system with ImageLab software.
Densitometry
Density quantification of protein bands in Western blots was 
performed with ImageJ software (The National Institutes of 
Health, Bethesda, MD; http://imagej.nih.gov/ij/). Quantification 
of proteins of interest was performed relative to the intensity of 
the respective loading controls and this ratio was set equal to one for 
the experimental control (e.g., vehicle-treated or untreated) group.
Transfections
Nucleofector kits for primary endothelial cells (Lonza, VVPI-
1001) in conjunction with Amaxa Nucleofector to transfect 
HPAECs with siGenome siRNA (Dharmacon, siGlo/non-targeting 
pool 1/non-targeting pool 2/SMPD1, D0016300205/D-001206-13/ 
D-001206-14/M-006676-01-0020) using the U-017 program per 
the manufacturer’s protocol. The concentration of siRNA listed 
was that achieved in 150 l of the inside cuvette prior to electro-
poration. After electroporation, cells were added to tissue culture 
dishes in 10 ml of full (containing all growth supplements) medium. 
The medium was changed 18 to 24 h after electroporation. Cells 
were harvested at 48 or 72 h after transfection, as indicated.
Quantitative PCR
Cells were washed with ice-cold PBS, gently scraped in ice-cold 
PBS, centrifuged at high speed for 10 min, supernatant removed, 
and pellet snap-frozen in liquid nitrogen. RNA was extracted with 
a GenElute mammalian total RNA mini kit (Sigma, RTN70-1KT) 
per the manufacturer’s protocol, and cDNA was reverse tran-
scribed with a high capacity cDNA reverse transcription kit with 
RNase inhibitor (Applied Biosystems, 4374966). Using SYBR Select 
Master Mix (Applied Biosystems, 4472908) and SMPD1/PGK1 
primers (Qiagen, PPH02494A/PPH02049A), 25 ng of cDNA 
was amplified on an ABI 7500 real-time PCR system (Applied 
Biosystems).
Immunofluorescence
HPAECs were cultured (125,000 cells per well) on 18 mm glass 
coverslips (VWR, 48380046) residing in 12-well dishes (Costar, 
3513) coated with a gelatin-based coating solution (Cell Biologics, 
6950) and were, after treatment and fixation with formaldehyde, 
exposed to rabbit anti-TFEB polyclonal antibody, Alexa Fluor 555 
conjugated (Bioss, bs-5137R-A555), and mounted with SlowFade 
Gold Antifade reagent with DAPI (Invitrogen, S36939) to micro-
scope slides (Thermo Fisher, 12-544-3). Images were taken on a 
Nikon Eclipse 80i microscope.
BEAS2b cells that stably express eGFP-LC3B were cultured in 
4-well Lab-Tek (Thermo Fisher Scientific, 154526) slides (50,000 
cells per well). After treatment and fixation with formaldehyde, 
they were probed for lysosome-associated membrane protein 1 
(LAMP1) by being exposed to rabbit anti-LAMP1 (Cell Signaling 
Technology, 9091), Alexa Fluor 594 (Thermo Fisher, A20185), 
and mounted with SlowFade Gold Antifade reagent with DAPI 
(Invitrogen, S36939) to coverslips (Thermo Fisher, 12-544-14) 
and imaged on a Nikon Eclipse 80i microscope.
Electron microscopy
After washing with ice-cold PBS (Fisher), cells were fixed with 
glutaraldehyde (Sigma, G7776) and formaldehyde (Thermo Fisher, 
28908), both at 2% in 0.1 M phosphate buffer for 30 min at room 
temperature. After two rounds of washing with PBS, cells were 
gently scraped in PBS, centrifuged for 10 min and further pro-
cessed by the Electron Microscopy Core Facility, Indiana Univer-
sity School of Medicine, which included post fixing, embedding, 
cutting, and mounting on slides. Images were taken with a Tecnai 
G2 12 Bio Twin (FEI, Hillsboro) equipped with an AMR CCD 
(Advanced Microscopy Techniques).
Stable clone generation
BEAS2b cells were cotransfected (Amaxa program U-017) 
with mammalian expression plasmid (pEF6/V5-His) expressing 
C-terminally tagged ASM (11), a kind gift from Dr. Yusuf Hannun 
(Stony Brook University) and mammalian expression plasmid 
expressing N-terminally tagged eGFP-LC3B under the control of 
a cytomegalovirus promoter (12) (a kind gift from William Jackson, 
Stanford University). To verify punctate formation with autophagic 
stimuli, cells were transiently transfected with eGFP-LC3B plasmid 
and treated with chloroquine (supplemental Fig. S1A). Selection 
pressure was applied with Geneticin (Santa Cruz, sc29065) for sev-
eral passages. The cotransfected cells were passaged several times 
and the overexpression of eGFP-LC3B confirmed by immunoblot 
(supplemental Fig. S1).
Differential centrifugation
Cells were cultured until 80–90% confluent and then treated as 
indicated, followed by medium removal and ice-cold Accutase (10 ml) 
addition to dishes. All reagents and centrifuges were kept at 4°C 
during all procedures. Cells were collected by pipetting and were 
spun at 500 g for 5 min. Pellets were suspended in 1 ml of PBS and 
spun again at 500 g for 5 min. After removing supernatants, the 
pellets were suspended in solution B from Axis-Shield Application 
S53 plus phosphatase and protease inhibitors. An aliquot was 
immediately taken and spun at 500 g for 5 min to prepare whole cell 
samples. After 25 min, each of the 10 samples generated was homog-
enized separately (30 strokes) in a 1 ml Dounce homogenizer with 
pestle B. Samples were then spun at 16,000 g for 5 min. The super-
natant was labeled cytosolic fraction and the remaining pellet 
was labeled organelle fraction. The organelle fraction was then 
resuspended in solution C, as per Axis-Shield Application S53. 
A 14 ml gradient with 2 ml discontinuous steps was made with v/v 
dilutions of OptiPrep as follows: 10% (sample), 12%, 14%, 16%, 
18%, 20%, and 25%, and spun at 150,000 g for 20 h. Fractions 
were collected from the bottom using a 3 ml syringe with a 4 inch 
16 gauge blunt needle. Six fractions were collected, each 150 l, 
starting with fraction six and either added to 4× Laemmli (Boston 
Bioproducts, NC9099736) for Western blotting or diluted with 
10 ml of PBS and spun at 150,000 g for 10 min. The supernatant 
was decanted and 1 ml of methanol was used to prepare the pellet 
for lipid extraction.
Lipid extraction
Methanol, water, and acetonitrile (HPLC grade) were pur-
chased from Burdick and Jackson (Muskegon, MI). Sph, dihydro 
(DH)Sph, a 17-carbon analog of Sph (C17-Sph), S1P, DHS1P, a 
17-carbon analog of S1P (C17-S1P), N-acylated (C14:0, C16:0, 
C18:1, C18:0, C20:0, C24:1, C24:0) Sphs (Ceramides, Cer), 
N-heptadecanoyl-Sph (C17:0-Cer), N-acylated sphingosylphosphor-
ylcholines (sphingomyelins, N-12:0, N-16:0, N-18:0, N-24:1, and 
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N-24:0), and glucosylceramides (N-16:0, N-24:1, N-24:0) were 
obtained from Avanti Polar Lipids (Alabaster, AL). N-D3-16:0-
glucosylceramide and N-D3-16:0-lactosylceramide were from 
Matreya LLC (State College, PA). The standards were dissolved in 
methanol (sphingoid base phosphates were dissolved with the 
addition of a trace amount of concentrated hydrochloric acid) 
and stored at 20°C. Pyridine (acetylation grade) and acetic anhy-
dride were products of Alltech Associates (Deerfield, IL).
Cellular lipids were extracted with a modified Bligh and Dyer 
procedure with the use of 0.1 N HCl for phase separation (13). 
C17-S1P (30 pmols), C17-Sph (30 pmols), N-C17:0-Cer (30 pmols), 
N-12:0-sphingosylphosphorylcholine (12:0-SM, 100 pmols), N-D3- 
16:0-glucosylceramide (25 pmol), and N-D3-16:0-lactosylceramide 
(25 pmol), employed as internal standards, were added during 
the initial step of lipid extraction. The extracted lipids were dis-
solved in ethanol and aliquots were taken out to determine total 
phospholipid content, as described by (13). Samples were con-
centrated under a stream of nitrogen, transferred to autosampler 
vials, and subjected to LC-MS/MS.
Pulse labeling of sphingolipid metabolites
Cells (HPAECs) were incubated (for 5 or 8 h, as indicated) in 
complete EBM-2 medium supplemented with L-[U-13C,15N]serine 
(50 mg/l; Cambridge Isotope Laboratories, Andover, MA). Imip-
ramine was added to cells at 3 or 5 h after the beginning of cell 
labeling, respectively. At the end of incubation, the medium was 
removed and lipids were extracted as described above. Quantita-
tion of label-incorporated sphingolipids was achieved by LC-MS/
MS by monitoring [M+3] isotopes in precursor and product ions, 
as described below.
LC-MS/MS
Analyses of sphingoid base-1-phosphates, ceramides, sphingoid 
bases, sphingomyelins, glycosylceramides, and lactosylceramides 
were performed by ESI-LC/MS/MS. The instrumentation 
employed was a Sciex 6500 QTRAP hybrid triple quadrupole lin-
ear ion-trap mass spectrometer (AB Sciex, Redwood City, CA) 
equipped with an Ion Drive Turbo V ionspray ionization source 
interfaced with a Shimadzu Nexera X2 UHPLC system. All lipid 
molecules and their derivatives were separated using an Ascentis 
Express RP-Amide 2.7 m 2.1 × 50 mm column and gradient 
elution from methanol:water:formic acid (65:35:0.5, 5 mM 
ammonium formate) to methanol:chloroform:water:formic acid 
(90:10:0.5:0.5, 5 mM ammonium formate). S1P and DHS1P were 
analyzed as bis-acetylated derivatives with C17-S1P as the internal 
standard employing negative ion ESI and multiple reaction moni-
toring (MRM) analysis, as described (14). Ceramides and sphin-
goid bases were analyzed with C17:0-Cer and C17-Sph as internal 
standards using positive ion ESI and MRM analysis (13). To facili-
tate sphingomyelin analysis and to avoid stable isotope overlap 
between phosphatidylcholines and sphingomyelins, lipids were 
hydrolyzed using a methylamine reagent for 2 h at 55°C (15). 
Reagents were evaporated with a nitrogen stream. The residual 
nonsaponified lipids were then dissolved in 0.2 ml of methanol 
and subjected to LC-MS/MS analysis of sphingomyelins. Sphingo-
myelins were detected as positive ions in MRM mode by a transi-
tion from the corresponding molecular ion to the m/z of 184 
(phosphocholine). Sphingomyelin quantification was achieved 
by creating standard curves of variable amounts of sphingomyelin 
standards (N-16:0-, 18:0-, 24:1-, and 24:0-sphingomyelins) versus 
a fixed amount of N-12:0-sphingomyelin (internal standard). The 
linearity and the correlation coefficients of the standard curves 
were obtained via linear regression analysis. Quantification of 
sphingolipid molecular species for which there were no standards 
available was performed using the best approximation from the 
available analogs with the most similar structure.
Mouse experiments
All experiments were approved by the IACUC (Indiana Univer-
sity School of Medicine, Indianapolis, IN) and conformed to the 
Public Health Service policy on humane care and use of laboratory 
animals as outlined by the Institute for Laboratory Animal Research 
guide of care and use of laboratory animals. Three-month-old 
female Smpd1+/+, Smpd1+/, or Smpd1/ mice (C57Bl/6 back-
ground strain), obtained from Dr. Edward Schuchman and 
Dr. Erich Gulbins, were used to harvest perfused lungs, which 
were snap-frozen in liquid nitrogen. Lung tissue was homogenized 
in the cell lysis buffer used for Western blotting. Homogenized 
tissue was sonicated for 2 s at 30% power, centrifuged at high 
speed, and the supernatant was removed as whole lung lysate.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 
(GraphPad Software, La Jolla, CA).
RESULTS
Effect of ASM inhibition on LYNUS signaling
First, using a fluorometric ASM activity assay, we mea-
sured the baseline activity of ASM in HPAECs and con-
firmed the marked inhibitory effect of imipramine (50 M, 
4 h) (supplemental Fig. S2), a tertiary amine tricyclic anti-
depressant known to increase the proteolytic degradation 
of lysosomal ASM (16). Pharmacological inhibition of ASM 
with imipramine significantly decreased the phosphoryla-
tion status of P70-S6k rapidly (within 1 h) and sustainably 
(for up to 24 h), as visualized by Western blot and quanti-
fied by densitometry (Fig. 1A–C). ASM inhibition also re-
duced mTOR phosphorylation (supplemental Fig. S3A), 
but did not affect the phosphorylation of Akt (supplemen-
tal Fig. S3B). Because ASM inhibition with imipramine may 
have nonspecific effects, we corroborated these results by 
targeting the transcript of the sphingomyelin phosphodies-
terase gene (SMPD1) with siRNA (1–3.33 M, 48–72 h). 
Compared with three nontargeting pools of siRNA that 
included fluorescently labeled siRNA (siGLO), SMPD1 
siRNA reduced SMPD1 transcript levels by 50%, as mea-
sured by quantitative (q)PCR (Fig. 1D) and markedly inhib-
ited ASM activity measured fluorimetrically (by 85%, 
Fig. 1E) or by radioactive assay (by 65%, data not shown). 
ASM knockdown with SMPD1 siRNA reduced the phosphory-
lation of both mTOR and P70-S6k, as detected by Western 
blot and quantified (P70-S6k) by densitometry (Fig. 1F, G). 
We next interrogated whether ASM inhibition activated 
TFEB, a transcription factor docked at LYNUS that re-
quires dephosphorylation for translocation to the nucleus. 
ASM inhibition was associated with loss of the “smear” 
appearance of immunoblotted TFEB seen in control condi-
tions, with the appearance of a lower molecular weight more 
resolved band, indicating loss of phosphorylation (Fig. 1H). 
ASM inhibition was associated with an apparent increase 
in both cytosolic and nuclear TFEB immunostaining, as 
detected by epifluorescence (Fig. 1I). Together, the inhibi-
tion of mTOR and its downstream target P70-S6k, TFEB 
dephosphorylation, and increased TFEB in the nucleus 
indicate that ASM inhibition decreases LYNUS function.
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Fig. 1. Effects of ASM inhibition on LYNUS signaling in HPAECs. A–C: Representative Western blots (A, B) and quantification by densi-
tometry (C) of phosphorylated (p)-P70-S6k and vinculin (loading control) following treatment with the ASM inhibitor, imipramine, or 
vehicle (water) for the indicated time (hours) and concentrations (micromoles). D, E: SMPD1 mRNA expression measured by qPCR and 
ASM activity detected by fluorimetry using a fluorescently labeled substrate (Amplex Red) following treatment with transfection reagent 
(mock), control siRNA [siGlo (n = 1)], nontargeting (NT) pools 1 or 2 siRNAs, or SMPD1 siRNA (each 3.33 M; 72 h) or left untreated (UT). 
F, G: Phosphorylated mTOR (pMTOR; at Ser 2448) and p-P70-S6k abundance detected by Western blotting (F) and quantified by densitom-
etry relative to actin loading control (G) following the indicated siRNA. Graphs show individual data points of independent experiments, 
means, and SEM; *** P  0.001 (ANOVA; Tukey’s post hoc test); * P  0.05 (Student’s t-test), respectively. H: Western blot of TFEB following 
imipramine treatment (50 M; for the indicated time). Note the absence of smear-like TFEB protein detection in ASM-inhibited cells. 
I: Representative fluorescence micrographs following immunostaining for TFEB (red) and nuclear staining (DAPI, blue; n = 3). Note the 
increased TFEB immunostaining in both the nucleus (yellow arrowhead) and cytoplasm (white arrow) in ASM-inhibited cells at 4 h following 
the addition of imipramine.
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ASM inhibition triggers autophagy
Because mTOR inhibits autophagy, we next determined 
whether baseline ASM activity in normal growth conditions 
is required not only to maintain LYNUS activity, but also to 
inhibit autophagy. Autophagosome abundance was first 
measured by the amount of intracellular LC3B-II. Pharma-
cological inhibition of ASM with imipramine (50–100 M 
for 2–24 h) increased LC3B-II levels, as detected by West-
ern blot and quantified by densitometry (Fig. 2A–D). 
Similarly, ASM knockdown with siRNA led to significant 
increases in LC3B-II, as detected by Western blot and quan-
tified by densitometry (Fig. 2E, F). To determine whether 
this effect extended to other types of cells than HPAECs, 
we used similar conditions of ASM inhibition (imipramine, 
50 M, 4 h) to treat other human endothelial cells, such as 
HLMVECs, HUVECs, human THP-1 monocyte cells, and 
the lung epithelial cell line, BEAS2b, and noted that 
all exhibited similar increases in LC3B-II (Fig. 2G, H). In 
human BEAS2b cells, we utilized electron microscopy to 
visualize morphological changes triggered by ASM inhi-
bition. Cells exhibited relatively few intra-cytoplasmic 
autophagic bodies during baseline conditions (Fig. 2I). In 
contrast, cells treated with the ASM inhibitor accumulated 
multiple large autolysosomal bodies with more heteroge-
neous content (Fig. 2I).
ASM inhibition induces autophagy with lysosomal 
degradative potential
To clarify whether the increased LC3B-II abundance fol-
lowing ASM inhibition is the result of increased produc-
tion of autophagosomes versus that of reduced clearance 
of autophagosomes produced at a basal rate, experiments 
were performed in HPAECs in the presence or absence of 
chloroquine, which increases lysosomal pH, diminishes 
the activity of acidic proteases, reduces autophagosome- 
lysosome fusion, and decelerates the degradation of LC3B-II 
associated with autophagosomes (autophagic flux). Com-
pared with cells treated with imipramine alone, those 
treated with both imipramine and chloroquine exhibited 
further increases in LC3B-II levels as well as p62 levels 
(Fig. 3A). This result suggests that autophagosome turn-
over is present in ASM-inhibited cells and that LC3B-II 
accumulation is more likely due to increased autopha-
gosome formation rather than a significant blockage in 
autophagic flux (17).
As a complementary approach to determine lysosomal 
degradation of autophagy following ASM inhibition, we 
used BEAS2b cells stably expressing eGFP-LC3B (Fig. 3B). 
The colocalization of eGFP-LC3B (green) and LAMP1 (red), 
a marker of endosomes and lysosomes, was assessed by 
immunofluorescence microscopy following ASM inhibition 
Fig. 2. Effect of ASM inhibition on autophagy. A–E: 
Representative Western blots (A, C, E) and quantifica-
tion by densitometry (B, D, F) of LC3B-I and -II pro-
tein abundance relative to vinculin (loading control) 
in HPAECs following ASM inhibition with imipramine 
at the indicated concentrations (A, B: 4 h) and time 
(C, D; 50 M), or with SMPD1 siRNA (E, F: 3.33 M, 
72 h). G: LC3B-I and -II and vinculin (loading control) 
detected by Western blot in HLMVECs, HUVECs, 
human monocytes (THP-1), or BEAS2b cells following 
imipramine treatment (50 M; 4 h). H: Relative abun-
dance of LC3B-II (vs. vinculin) in BEAS2b cells treated 
with imipramine (+) measured by densitometry. I: 
Representative electron microscopy micrographs of 
BEAS2b cells following ASM inhibition with imipra-
mine (50 M; 6 h). Note several small intracytoplasmic 
bodies in control cells (white arrow) compared with 
multiple large intracytoplasmic bodies with heteroge-
neous density in ASM-inhibited cells (black arrows). 
The graphs in B, D, F, and H show individual data 
points from independent experiments, mean ± SEM; 
***P  0.001 (ANOVA; Tukey’s post hoc test).
602 Journal of Lipid Research Volume 59, 2018
in the presence of chloroquine. Vehicle-treated cells exhib-
ited cytosolic diffuse green immunofluorescence with mini-
mal colocalization with LAMP1-positive (red) endolysosomal 
vesicles (Fig. 3B). Imipramine treatment increased the 
number of punctate eGFP-containing autophagic vesicles 
that colocalized with LAMP1, suggesting autophagolyso-
somal fusion (Fig. 3B). Cells cotreated with imipramine 
and chloroquine had more intracellular eGFP punctate 
vesicles, suggesting nonfused autophagosomes (Fig. 3B) 
when compared with imipramine treatment alone (Fig. 3B). 
Together, these results suggest that ASM inhibition induces 
autophagy with degradative potential.
ASM inhibition leads to decreased Sph levels
Because the sphingolipid metabolism is highly dynamic 
and organelle specific, we next determined levels of 
sphingolipid metabolites following ASM inhibition in 
whole cells and in lysosome-enriched fractions obtained 
by isopycnic separation. To analyze proximal changes in 
sphingolipids following ASM inhibition, we selected to 
measure these at the earliest time point (30 min) of 
detectable LYNUS alterations, such as decreased TFEB 
phosphorylation. Following subcellular fractionation, we 
noted that fraction six (in order of increasing density) con-
tained the mature forms of both cathepsin D and LAMP1, 
indicating lysosome enrichment (Fig. 4A). Fraction six 
also contained LC3B-II (Fig. 4A) as well as the nucleus 
marker, histone h3, and the mitochondrial marker, voltage-
dependent anion channel (VDAC) (not shown). Follow-
ing imipramine treatment, neither whole cell lysates nor 
the lysosome-enriched subcellular fraction exhibited 
decreased ceramides (Fig. 4B, C); instead, ceramides 
were modesty increased on account of less abundant spe-
cies (supplemental Fig. S4). Similarly, inhibition of ASM 
with imipramine did not significantly change sphingomy-
elins within this timeframe (supplemental Fig. S4) or for 
up to 24 h (data not shown). The most remarkable change 
in sphingolipid species following pharmacological ASM 
inhibition was a significant decrease in relative Sph levels 
(Fig. 4B). As a complementary approach, we transfected 
HPAECs with nontargeting pool 1, nontargeting pool 2, 
or SMPD1 siRNA (1–3.33 M; 48–72 h) and noted that, 
similar to imipramine, ASM knockdown significantly 
reduced Sph concentrations compared with control con-
ditions (Fig. 4C).
To further study how ASM inhibition caused Sph deple-
tion, we performed pulse labeling of de novo synthesized 
sphingolipids with U-[13C,15N]serine. Cells were allowed to 
incorporate the label for 5 or 8 h, of which the last 2 or 3 h, 
respectively, were in the presence of vehicle or imipramine. 
The quantitation of labeled and nonlabeled sphingolipid 
levels by MS/MS established that ASM inhibition had 
modest effects on sphingomyelin levels and, indeed, did 
not reduce, but rather increased, ceramide levels at the 
Fig. 3. Effect of ASM inhibition on lysosomal degra-
dative potential. A: Representative Western blot of 
p62, LC3B-II, and vinculin (loading control) follow-
ing treatment with the ASM inhibitor, imipramine 
(50 M, 4 h) and low-dose chloroquine (Chlq, 5 M, 
4 h) or rapamycin (Rapa, 1 M, 4 h). B: Representative 
immunofluorescence images of bronchial epithelial 
cells (BEAS2b cells) expressing eGFP-LC3B (green) 
immunostained with LAMP1 antibody (red; white 
arrows) following treatment with imipramine (50 M, 
4 h) and/or chloroquine (50 M, 4 h). Note the 
increased green punctae in imipramine-treated cells 
(indicating increased autophagosomes) and relatively 
low red signal (indicating nonfused lysosomes); intense 
green punctae in imipramine-chloroquine cotreated 
cells (yellow arrowhead, indicating increased undi-
gested autophagosomes); increased red immunofluo-
rescence (white arrow) along with green punctae 
(yellow arrowhead), indicating autophagosomes that 
do not fuse with lysosomes in chloroquine-treated cells.
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Fig. 4. Effect of ASM inhibition on sphingolipids. A: Representative immunoblots of markers of lysosome (cathepsin D) and of endomem-
branes (LAMP1 and the autophagy marker, LC3B-II) in the indicated subcellular fractions (fractions 1–6, obtained by isopycnic separation) 
of HPAECs treated with imipramine (50 M, 30 min) or control vehicle. Note the increased abundance of autophagosomal marker LC3B-II 
in all imipramine-treated fractions. B: Relative levels of ceramide and Sph in HPAECs exposed to the ASM inhibitor, imipramine, compared 
with cells exposed to vehicle, measured by MS/MS. Each data point represents an independent experiment. Data are expressed as mean ± 
SEM; *P  0.05 imipramine versus control. C: Absolute Sph levels in HPAECs transfected with nontargeting pool 1, nontargeting pool 2, or 
SMPD1 siRNA (1–3.33 M; 48–72 h). Each data point represents an independent experiment. Data are expressed as mean ± SEM; *P  0.05. 
Cer, ceramide. D: Levels of U-[13C,15N]serine-labeled and unlabeled sphingolipids measured by MS/MS following treatment with vehicle 
(Veh) or imipramine (ASM inh) for the indicated time. The horizontal bar represents the mean.
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expense of markedly decreasing Sph and S1P production 
(Fig. 4D). Because sphingolipid metabolites, such as dihy-
droceramide, DHSph, and glycosylceramides, did not signifi-
cantly change following imipramine incubation (Fig. 4D), 
these data indicate that inhibition of ASM was intimately 
linked to inhibition of acid ceramidase. It should be also 
noted that it was mostly the levels of short chain cerami-
des (14:0; 16:0, and 18:0) that were increased following 
imipramine (supplemental Fig. S4A), which was con-
firmed in pulse labeled experiments where 16:0 ceramide 
species, but not 24:1 (supplemental Fig. S4B) or 24:0 
(data not shown), were increased as a result of imipra-
mine treatment, suggesting that the effect of the meta-
bolic block at the ASM/acid ceramidase level is linked to 
the preferential accumulation of newly formed short-
chain ceramide molecules.
ASM inhibition increases LC3B-II levels and decreases 
Sph levels in vivo
To investigate whether the marked effects of ASM inhibi-
tion on autophagy are recapitulated in vivo, we mea-
sured for LC3B-II by Western blot in whole lung lysates of 
Smpd1+/ mice, known to exhibit 50% reductions in ASM 
activity compared with wild-type mice (18). Smpd1+/ lungs 
had an increased abundance of LC3B-II compared with 
Smpd1+/+ littermates (Fig. 5A). Sph levels were signifi-
cantly lower in the lungs of Smpd1+/ mice compared with 
Smpd1+/+ mice, indicating that Sph abundance depends on 
ASM (Fig. 5B) and that the elevation in LC3B-II following 
ASM inhibition is associated with decreased Sph both in 
vitro and in vivo.
DISCUSSION
Our study demonstrates, for the first time, an important 
homeostatic functional relationship between ASM and 
LYNUS activity, indicating that a baseline ASM activity is 
required for mTOR signaling and autophagy inhibition. 
Our data indicate that, upon ASM inhibition, mTOR fails 
to phosphorylate P70-S6k and TFEB becomes dephosphor-
ylated and translocates to the nucleus, events associated 
with overall increased TFEB abundance and signs of 
increased autophagy with degradative potential. Although 
the precise mechanism underlying the functional connec-
tion between ASM-LYNUS remains to be elucidated, our 
data suggest that it may be linked to the critical role of ASM 
in sustaining Sph levels in the lysosome. These new find-
ings, that implicate basal ASM activity in fundamental lyso-
some functions, complement a large body of knowledge 
relating ASM hyperactivation to lysosome (dys)function 
during multiple conditions.
ASM inhibition reduced the phosphorylation of mTOR 
at Ser 2448, which typically occurs through Akt pathway 
signaling and is required for mTOR catalytic activity. 
Because the phosphorylation of Akt was unaffected following 
ASM inhibition, the effect is likely to occur downstream of 
Akt. The phosphorylation of mTOR at Ser 2448 is also 
dependent, through a feedback loop, on the phosphorylation 
(activation) of its downstream target, P70-S6k (19), which 
was markedly decreased by ASM inhibition. It is therefore 
likely that ASM activity participates in the feedback signal-
ing between P70-S6k and mTOR Ser 2448 phosphorylation. 
How this occurs remains elusive. We hypothesized that these 
effects may be ascribed to signaling or structural effects of 
sphingolipids metabolized by ASM. Because we noted 
increased, rather than decreased, ceramide upon ASM 
inhibition, this may inhibit mTOR activity via the SET-PP2A 
signaling axis (20), but the measured increases were rather 
modest. However, because lysosomal ASM-generated 
ceramides are spatially constrained within lysosomes, they 
may contribute to lysosomal membrane biophysical prop-
erties, such as stiffness. These membrane perturbations 
may affect docking and signaling by interfering with the 
insertion of farnesylated complex anchors or by rearrang-
ing microdomains. Nevertheless, because Sph was the most 
marked and consistently affected sphingolipid following 
ASM inhibition, it is likely that the decreased Sph content 
in the lysosome may have significantly altered the lysosomal 
calcium efflux, ultimately affecting TFEB phosphorylation 
through calcineurin (21). Alternatively, subsequent reduc-
tions in S1P levels may be implicated, although increased, 
rather than decreased, intracellular S1P has been associ-
ated with triggering autophagy (22). The pro-autophagic 
effect of S1P production and the importance of the subcel-
lular localization of S1P accumulation have recently been 
described in neuronal cells (23–25). This body of work 
suggests that the autophagy triggered by ASM inhibition, 
which was associated with decreased S1P levels, occurs via a 
different mechanism than by S1P overproduction.
The consistent decrease in Sph upon ASM inhibition 
has been previously reported and suggests either reduced 
Fig. 5. Effect of ASM inhibition on lung autophagy and Sph levels 
in vivo. A, B: Representative immunoblot of LC3B-I and -II and vin-
culin (loading control) in whole lung lysates of mice expressing 
baseline levels (Smpd1+/+) or deficient (Smpd1+/ and Smpd1/) in 
ASM (each lane represents a separate mouse lung lysate of each 
genotype). B: Sph levels in whole lungs of Smpd1+/+, Smpd1+/, and 
Smpd1/) mice. Graph shows individual data from distinct animals, 
means, and SEM. *P  0.05, ***P  0.001 (ANOVA; Dunnett’s post 
hoc test).
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substrate (ceramide) for acid ceramidase to produce Sph 
or indicates that inactivation of ASM, which is known to 
form a physical complex with acid ceramidase, directly 
inhibits the ceramidase activity (26). We could not document 
decreased substrate (ceramide) availability for acid cerami-
dase and our pulse-labeling experiments indicate that ASM 
inhibition rapidly causes marked inhibition of acid cerami-
dase activity, as well. Because Sph readily crosses lysosomal 
membranes, reduced Sph, which could generate ceramide 
via recycling in the endoplasmic reticulum, may compen-
satorily stimulate de novo ceramide synthesis or reduce 
ceramide utilization for complex sphingolipid synthesis 
(27) (see schematic in supplemental Fig. S5). Pulse-labeling 
analyses did suggest modest stimulation of de novo synthesis 
of several ceramide species (C14:0 to C18:0), of which the 
most abundant was the palmitoyl (C16:0) ceramide. These 
effects may explain why ceramide levels were not found to be 
decreased for up to 72 h following ASM inhibition and 
implicate decreased Sph as a driver of autophagy, rather than 
increases in previously described autophagic drivers, S1P 
or ceramide. Furthermore, the subcellular localization of 
lower levels of Sph may be important, because an inhibi-
tor of de novo sphingolipid production in the endoplas-
mic reticulum did not increase LC3B-II levels (28); whereas, 
we show here that inhibition of Sph production in the 
lysosome effectively triggered lysosomal autophagy. How-
ever, the sphingolipid metabolism is notoriously reactive to 
perturbations, and we recognize that we have not analyzed 
the kinetics of all sphingolipid species’ changes following 
ASM inhibition. Another limitation of our study is the lack of 
direct correlation of the magnitude of the SMPD1 mRNA 
decrease following knockdown with the marked enzymatic 
activity inhibition that followed this approach, especially in 
the absence of documented ASM protein levels, which are 
known to have a relatively short half-life of only 5 h (16).
Our results, using chloroquine, immunofluorescence 
of LC3B-II and lysosome markers, and electron micros-
copy, indicate that ASM inhibition triggered lysosomal 
autophagy with preserved flux, which is defined as degra-
dation of autophagosomes within lysosomes. Further-
more, the finding that LC3B-II was absent in the less dense 
subcellular fractions of control cells, but present in all 
fractions of ASM-inhibited cells, indicates the presence of 
elongating phagophores (29), which suggests rapid induc-
tion of autophagy following ASM inhibition. Electron 
microscopy images not only demonstrated the increased 
number of structures suggestive of autophagic vesicles fol-
lowing ASM inhibition, but also showed that the content of 
these vesicles was more heterogeneous, a feature previously 
described to reflect various stages of cargo degradation in 
autophagolysosomes (30). This finding, in the context of 
the rest of our other data, may indicate that autophagic 
induction and pleiotropic fusion may occur simultaneously 
following ASM inhibition. The autophagic activity follow-
ing ASM inhibition was associated with lysosomal integ-
rity, as appreciated by immunofluorescence with LAMP1 
antibodies, acridine orange staining (data not shown), 
and electron microscopy. Autophagy was also associated 
with preserved cell viability, as assessed by annexin V and 
propidium iodide staining and thymidine incorporation 
(data not shown). Our results, obtained in primary cells, 
immortalized macrophages, or lung epithelial cell lines, 
differ from those reported in a cancer cell line that over-
expressed eGFP-LC3, which showed that desmethylclo-
mipramine, a metabolite of clomipramine that structurally 
resembles imipramine, blocked autophagic flux (31). Such 
a discrepancy may be related to differences in baseline 
ASM or mTOR activities among different cell types, rather 
than the use of a different pharmacological inhibitor. Our 
results do not contradict the report that autophagosomes 
may move more slowly in the absence of ASM due to 
decreased calcium efflux from the lysosome (32), because 
our data indicate that ASM inhibition induces autophagy 
and that the autophagic flux is present, and we cannot dis-
pute that such flux may occur at slower rates than in other 
conditions of autophagy.
In conclusion, our study demonstrates that lysosomal 
ASM is an important determinant of homeostatic mTOR 
signaling and LYNUS function, which suggests that this 
sphingolipid metabolic enzyme is an important regulator 
of autophagy. The clinical implications of these results 
relate to the widespread use of antidepressants in various 
clinical settings, and their potential to affect conditions 
where initiation of autophagy with degradative potential is 
desirable.
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